$35 Million is the total value of CAXTON CORP's 10 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SBBP | STRONGBRIDGE BIOPHARMA PLC | $25,626,000 | +97.9% | 5,394,994 | 0.0% | 73.15% | +65.6% | |
| AGRX | Sell | AGILE THERAPEUTICS INC | $5,204,000 | -57.0% | 1,623,567 | -23.5% | 14.86% | -64.0% |
| BRKB | BERKSHIRE HATHAWAY INC DELcl b new | $1,491,000 | +2.3% | 8,945 | 0.0% | 4.26% | -14.4% | |
| Buy | GARRISON CAP INC | $646,000 | +32.6% | 66,073 | +26.8% | 1.84% | +11.0% | |
| CMFN | Buy | CM FIN INC | $540,000 | +35.7% | 53,204 | +24.4% | 1.54% | +13.5% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $395,000 | +10.0% | 13,263 | +0.2% | 1.13% | -7.9% |
| ADNT | ADIENT PLC | $344,000 | +23.7% | 4,737 | 0.0% | 0.98% | +3.6% | |
| TMH | Buy | TEAM HEALTH HOLDINGS INC | $336,000 | +2.4% | 7,713 | +2.2% | 0.96% | -14.3% |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $289,000 | – | 1,992 | +100.0% | 0.82% | – |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $162,000 | -23.6% | 20,802 | +2.2% | 0.46% | -36.1% |
| SCM | Exit | STELLUS CAP INVT CORP | $0 | – | -15,593 | -100.0% | -0.64% | – |
| ACSF | Exit | AMERICAN CAP SR FLOATING LTD | $0 | – | -17,931 | -100.0% | -0.73% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -21,923 | -100.0% | -1.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.